OssDsign is granted a new European patent related to the company’s ceramic material technology
The European Patent Office (EPO) has issued that it has granted OssDsign AB (publ) (“OssDsign” or the “Company”) a new European patent related to the company’s ceramic material technology. This further strengthens OssDsign’s extensive patent protection in the field of ceramic material formulations and their applications for medical use.
OssDsign’s material protected technology provides OssDsign’s implants with unique biological properties, which has been reported in scientific publications. The protection of this technology is further strengthened by the grant of this patent. The patent covers the European market and is valid to 2033. Previously patents of the same family have been granted in other key markets such as USA and Japan.
For further information, please contact:
Anders Lundqvist, CEO, OssDsign AB
Tel: +46 73 206 98 08, email: al@ossdsign.com
Certified Adviser
The Company’s Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.
About OssDsign
OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.
Tags: